HRT Financial’s Sonnet BioTherapeutics SONN Stock Holding History

HRT Financial’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-74,265	Closed	-$340K	–	3978
2025 Q3	$340K	Buy	+74,265	New	+$329K	﹤0.01%	2103
2023 Q3	–	Sell	-156	Closed	-$13K	–	3043
2023 Q2	$13K	Buy	+156	New	+$11K	﹤0.01%	2149
2023 Q1	–	Sell	-91	Closed	-$18K	–	3148
2022 Q4	$18K	Buy	+91	New	+$19.9K	﹤0.01%	2187
2022 Q2	–	Sell	-5	Closed	-$4K	–	3674
2022 Q1	$4K	Buy	+5	New	+$4.23K	﹤0.01%	2967

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

HRT Financial's SONN Position: Q4 2025 in Review

HRT Financial sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 74,265 shares — an estimated $340K sold.

HRT Financial first reported a position in SONN in Q1 2022 and held it in 4 quarters. The position peaked at $340K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

HRT Financial reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 74,265 Sonnet BioTherapeutics shares in Q4 2025, an estimated $340K.
HRT Financial first reported a position in Sonnet BioTherapeutics in Q1 2022 and held it in 4 quarters.
HRT Financial's Sonnet BioTherapeutics position peaked at $340K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.